Kineta enters research collaboration and license agreement with Pfizer
- by By Team ABLE - 19 Dec, 2018
Kineta Immuno-Oncology LLC (KIO)has entered into a strategic research collaboration with Pfizer Inc. to develop RIG-I agonist immunotherapies for the treatment of cancer.
The research collaboration and license agreement grants to Pfizer the exclusive rights to KIO's RIG-I screening platform and related compounds and technologies.
The companies will collaborate to develop and test small molecule agonists that target RIG-I, an innateimmunostimulatorypathwaythat can elicit immunogenic cell death (ICD) in tumors, providing both direct tumor cell killing and enhanced anti-tumor immune responses.
Under the terms of the agreement, KIO will receive a$15 millionupfrontpayment and will be eligible to receive up to$505 millionin potential research, development and sales milestone payments. Additionally, KIO is eligible to receive tiered royalties on net sales.
Pfizer will fund RIG-I target-related research conducted by Kineta for an initial period of three years, after which Pfizer will be responsible for further development and commercialization of product candidates.
The companies will collaborate to develop and test small molecule agonists that target RIG-I, an innate immunostimulatory pathway that can elicit immunogenic cell death (ICD) in tumors.